Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging
By S. Harlow, Margery L S Gass, J. Hall, R. Lobo, P. Maki, R. Rebar, Sherry Sherman, P. Sluss, T. D. de Villiers. Menopause, 2012
2,286 citations recorded by the source corpus.
ObjectiveThe aim of this article is to summarize the recommended updates to the 2001 Stages of Reproductive Aging Workshop (STRAW) criteria. The 2011 STRAW + 10 reviewed advances in understanding of the critical changes in hypothalamic-pituitary-ovarian function that occur before and after the final menstrual period. MethodsScientists from five countries and multiple disciplines evaluated data from cohort studies of midlife women and in the context of chronic illness and endocrine disorders on change in menstrual, endocrine, and ovarian markers of reproductive aging including antimüllerian hormone, inhibin-B, follicle-stimulating hormone, and antral follicle count. Modifications were adopted by consensus. ResultsSTRAW + 10 simplified bleeding criteria for the early and late menopausal transition, recommended modifications to criteria for the late reproductive stage (Stage −3) and the early postmenopause stage (Stage +1), provided information on the duration of the late transition (Stage −1) and early postmenopause (Stage +1), and recommended application regardless of women’s age, ethnicity, body size, or lifestyle characteristics. ConclusionsSTRAW + 10 provides a more comprehensive basis for assessing reproductive aging in research and clinical contexts. Application of the STRAW + 10 staging system should improve comparability of studies of midlife women and facilitate clinical decision making. Nonetheless, important knowledge gaps persist, and seven research priorities are identified.
Subfields: Endocrinology, Diabetes and Metabolism, Public Health, Environmental and Occupational Health, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/e7ea2de7522aa05cc63e0f148bededbd1192dff4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Bruce Fischl
- David H. Salat
- Douglas N. Greve
- Randy L. Buckner
- Deanna M. Barch
- Matthew F. Glasser
- Trey Hedden
- Anders M. Fjell
Citations in the corpus
- The Lifespan Human Connectome Project in Aging: An overview (2018, positive): “We will stage menopause objectively using validated criteria (Harlow et al., 2012) and obtain multiple hormonal measures for all participants (across age and gender) for comparison (see Section 5.1).”
- Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. (2015, background): “Menopausal transition (or perimenopause) An interval preceding the menopause characterized by variations in menstrual cycle length and bleeding pattern, mood shifts, vasomotor, and vaginal symptoms and with rising FSH levels and falling anti-Mullerian hormone and inhibin B levels, which starts durin”